Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 154,900 shares of the company’s stock, valued at approximately $9,159,000. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.11% of Adaptive Biotechnologies as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in shares of Adaptive Biotechnologies by 511.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 83,791 shares of the company’s stock valued at $4,955,000 after purchasing an additional 70,091 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at approximately $382,000. Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of Adaptive Biotechnologies by 102.1% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 111,940 shares of the company’s stock valued at $6,619,000 after buying an additional 56,545 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Adaptive Biotechnologies by 2.0% in the 4th quarter. Principal Financial Group Inc. now owns 323,287 shares of the company’s stock worth $19,115,000 after acquiring an additional 6,213 shares in the last quarter. Finally, Truist Financial Corp acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $273,000. Hedge funds and other institutional investors own 80.80% of the company’s stock.
A number of analysts have recently commented on the stock. Zacks Investment Research cut shares of Adaptive Biotechnologies from a “hold” rating to a “sell” rating in a research note on Tuesday, January 12th. BTIG Research lifted their price target on Adaptive Biotechnologies from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, January 19th. Morgan Stanley boosted their price target on Adaptive Biotechnologies from $46.00 to $60.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 4th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $63.00 target price (down previously from $74.00) on shares of Adaptive Biotechnologies in a research note on Tuesday, March 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Adaptive Biotechnologies presently has a consensus rating of “Hold” and a consensus target price of $59.33.
NASDAQ ADPT opened at $40.63 on Thursday. Adaptive Biotechnologies Co. has a fifty-two week low of $23.68 and a fifty-two week high of $71.25. The firm has a market capitalization of $5.66 billion, a P/E ratio of -42.77 and a beta of 0.35. The stock’s fifty day moving average is $46.63 and its two-hundred day moving average is $52.54.
Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, February 23rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.04). Adaptive Biotechnologies had a negative return on equity of 20.15% and a negative net margin of 132.32%. The firm had revenue of $30.19 million for the quarter, compared to analyst estimates of $27.08 million. On average, equities research analysts predict that Adaptive Biotechnologies Co. will post -1.08 earnings per share for the current fiscal year.
In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 8,400 shares of Adaptive Biotechnologies stock in a transaction dated Tuesday, January 19th. The shares were sold at an average price of $70.43, for a total transaction of $591,612.00. Following the completion of the sale, the chief executive officer now directly owns 1,769,880 shares in the company, valued at $124,652,648.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Chad M. Robins sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 26th. The stock was sold at an average price of $63.53, for a total transaction of $635,300.00. Following the completion of the transaction, the chief executive officer now owns 1,765,930 shares in the company, valued at $112,189,532.90. The disclosure for this sale can be found here. Insiders sold 1,264,609 shares of company stock valued at $65,272,781 over the last quarter. 22.20% of the stock is currently owned by company insiders.
Adaptive Biotechnologies Profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.
Recommended Story: How mutual funds make money
Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Co. (NASDAQ:ADPT).
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.